PLIANT THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.19 USD | -5.21% |
|
-15.76% | -32.69% |
Financials (USD)
| Sales 2024 * | 1.54M | Sales 2025 * | 5.81M | Capitalization | 734M |
|---|---|---|---|---|---|
| Net income 2024 * | -201M | Net income 2025 * | -241M | EV / Sales 2024 * | 242 x |
| Net cash position 2024 * | 362M | Net cash position 2025 * | 377M | EV / Sales 2025 * | 61.5 x |
| P/E ratio 2024 * |
-3.7
x | P/E ratio 2025 * |
-3.38
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pliant Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -5.21% | ||
| 1 week | -15.76% | ||
| Current month | -18.19% | ||
| 1 month | -16.51% | ||
| 3 months | -26.17% | ||
| 6 months | -10.04% | ||
| Current year | -32.69% |
1 week
12.00
14.15
1 month
12.0015.63
Current year
12.0019.62
1 year
12.0030.85
3 years
3.9736.64
5 years
3.9743.92
10 years
3.9743.92
| Managers | Title | Age | Since |
|---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
| - | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 18-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 21-01-11 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 16-06-30 |
Gayle Crowell
BRD | Director/Board Member | 73 | 20-01-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.16% | 2 M€ | -.--% | ||
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 237 M€ | -1.30% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.05% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 12.19 | -5.21% | 357,215 |
| 24-04-17 | 12.86 | -3.02% | 267,216 |
| 24-04-16 | 13.26 | -2.14% | 427,232 |
| 24-04-15 | 13.55 | -4.24% | 267,556 |
| 24-04-12 | 14.15 | -2.21% | 214,720 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvÃ6 and αvÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvÃ8 and αvÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.19
USD
Average target price
43
USD
Spread / Average Target
+252.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.69% | 734M | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- PLRX Stock
